Cosmo Announces Leadership Changes
Dublin, Ireland--(Newsfile Corp. - April 25, 2024) - Cosmo Pharmaceuticals N.V. (SIX: COPN) (FSE: C43) (“Cosmo”) today announced the appointment of Giovanni Di Napoli as its new Chief Executive Officer, along with changes to its Board of Directors, at the upcoming Annual Gene
2024-04-25 1:32 AM EDT
Cosmo and Medtronic Unveil the Future of AI in GI: Genius Summit 2024 Reveals Innovations and Collaborations That Advance Endoscopic Care
Dublin, Ireland--(Newsfile Corp. - April 12, 2024) - Cosmo Pharmaceuticals N.V. (SIX: COPN) (FSE: C43) (“Cosmo”) announces that Medtronic plc (NYSE: MDT), a global leader in healthcare technology, presented at the Genius Summit 2024 the latest advancements in artificial intelligence (AI) for endoscopic care by unveiling ColonPRO™, the latest generation software for the GI Genius™ intelligent endoscopy system developed by Cosmo IMD, along with a new strategic collaboration designed to enhance...
2024-04-12 1:17 AM EDT
Cosmo Reports Excellent Preliminary Unaudited Full Year 2023 Core Financial Results - Record Guidance for 2024 - Doubles Dividend to 2.00 per Share
Dublin, Ireland--(Newsfile Corp. - March 20, 2024) - Cosmo Pharmaceuticals N.V. (SIX: COPN) (FSE: C43) (“Cosmo”) today announced its preliminary unaudited results for the financial year 2023. Financial highlights Cosmo delivered strong growth across its core business in 2023. The company continues to make excellent progress on execution of its strategy with the a
2024-03-20 3:18 AM EDT
Cosmo Pharmaceuticals Announces Approval of Winlevi(R) in Australia
Dublin, Ireland--(Newsfile Corp. - March 19, 2024) - Cosmo Pharmaceuticals N.V. (SIX: COPN) (FSE: C43) (“Cosmo”) reported today that its partner Sun Pharmaceutical Industries Limited (Reuters: SUN.BO) (Bloomberg: SUNP IN), (NSE: SUNPHARMA) (BSE: 524715) (“Sun Pharma”) has announced that the Australian Therapeutic Goods Administration (TGA) has granted regulatory approval for Winlevi® (clascoterone cream 1%). Winlevi® is indicated for the topical treatment of acne vulgaris in patients 12 years...
2024-03-19 2:40 AM EDT
Invitation to Cosmo's Investor Day and Full-Year 2023 Webcast - Zurich, 20 March 2024
Dublin, Ireland--(Newsfile Corp. - January 25, 2024) - Cosmo Pharmaceuticals N.V. (SIX: COPN) (FSE: C43) (“Cosmo”) announced today that it will publish its Full-Year 2023 results on Wednesday, 20 March 2024 at 7:00 am CET. FY 2023 Results Webcast Cosmo invites investors, financial analysts and business/life sciences journalists to a live video webcast presentation which will follow at 11:00 am CET with Mauro Ajani, Chairman, and Alessandro Della Chà, CEO, to discuss the financial and...
2024-01-25 1:30 AM EST
Cosmo Pharmaceuticals and Medtronic Forge Ahead in AI-Driven Care
Dublin, Ireland--(Newsfile Corp. - December 11, 2023) - Cosmo Pharmaceuticals (SIX: COPN) (XETRA: C43) (“Cosmo”) announces that its subsidiary Cosmo Intelligent Medical Devices has entered into a definitive agreement to expand its partnership with Medtronic plc (NYSE: MDT), a global leader in healthcare technology. This AI-driven partnership will further capitalize on the achievements already realized with the GI Genius™ intelligent endoscopy module, offering continued innovation and scalable...
2023-12-11 2:02 AM EST